Analysis of drug gene detection after intracranial drug-coated balloon operation

[Objective] To observe the difference between antiplatelet therapy after drug-coated balloon angioplasty guided by drug gene detection and conventional antiplatelet therapy, and to evaluate the benefit of drug gene guided medication. [Methods] 80 elderly patients who underwent drug-coated balloon angioplasty for intracranial artery stenosis from June 2022 to May 2023 in the Department of Neurology I of the Fifth People ’s Hospital of Jinan were selected as the study subjects. According to the random number table method, the patients were divided into a drug gene detection group(group A) and a non-drug gene detection group(group B), with 40 cases in each group. After half a year and 1 year of treatment, digital subtraction angiography, brain magnetic resonance angiography and brain computed tomography angiography were used to assess the vascular status and compare the occurrence of endpoint events. [Results] Six months after operation, there was no significant difference in coagulation indexes between the two groups (P > 0.05). There was no significant difference in epistaxis, gingival bleeding and urinary bleeding between the two groups (P > 0.05); the gastrointestinal bleeding rate in group A was lower than that in group B (P < 0.05); the total number of haemorrhagic events in group A was lower than those in group B (P < 0.05). After 1-year follow-up, the overall endpoint events in group A were lower than those in group B, and the difference had a statistical significance (P < 0.05). [Conclusion] After drug-coated balloon angioplasty, the selection of antiplatelet drugs after drug gene detection can reduce the short-term risk of bleeding, improve the long-term prognosis and delay the occurrence of endpoint events in elderly patients .